


AYRTON DRUG MANUFACTURING LTD
Un-Audited Statement of Financial Position
For the Third Quarter Ending 31st March, 2018

	31/03/2018 GHC	31/03/2017 GHC
Non current assets		
Property, plant and equipment	7,475,616	7,355,153
Intangible	227	23,724
Deferred tax assets	420,257	-
	7,896,100	7,378,877
Current assets		
Inventories	10,685,524	10,488,415
Trade and other receivable	12,351,941	10,800,380
Amount due from Holding company	5,322,526	
Income Tax Receivable	-	
Cash and bank	195,236	276,179
Total Current Assets	28,555,227	21,564,974
Total Assets	36,451,326	28,943,852
Equity and liabilities		
Equity		
Issued capital	4,475,000	4,475,000
Other capital reserve	1,739,436	1,739,436
Income surplus	13,163,243	12,394,361
Total equity	19,377,679	18,608,797
Non-current liabilities		
Deferred tax	-	154,458
Current liabilities		
Trade and other payable	4,467,127	4,409,242
Amount due to holding company	1,036,406	1,036,406
Income tax payable	1,264,756	97,325
Short term borrowings	10,305,358	4,637,625
Total Liabilities	17,073,647	10,335,055
Total Equity and liabilities	36,451,326	28,943,852

Signed
 Director
 Yaw Opare-Asamoah



Signed
 Director
 Nik Amarteifio



PHILIPUS NII KAI AMARTEIFIO

AYRTON DRUG MANUFACTURING LTD**Un-Audited Statement of Profit or Loss and other Comprehensive****For the Third Quarter Ending 31st March, 2018**

	31/03/2018	31/03/2017
	GHC	GHC
Revenue	26,945,467	27,113,709
Cost of sales	<u>(13,560,191)</u>	<u>(12,820,351)</u>
Gross profit	13,385,276	14,293,358
Other income	-	745,562
Selling and distribution costs	(2,852,224)	(4,302,305)
Administrative expenses	(7,128,972)	(5,982,747)
Operating Profit/(loss)	3,404,080	4,753,868
Finance costs	(1,326,844)	(939,764)
Profit/(loss) before tax	2,077,236	3,814,104
Income tax expense	<u>(473,533.79)</u>	<u>(693,310)</u>
Profit/(loss) after tax	<u>1,603,702</u>	<u>3,120,794</u>
No.of shares	215,000,000	215,000,000
Earnings per share	0	0

